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Abstract
Introduction:  Mesothelioma is a cancer strongly linked to exposure to
carcinogenic minerals, especially asbestos. The aim of the study was to detect
the incidence of malignant pleural mesothelioma (MPM) in Egypt, to clarify the
impact of occupational and environmental risk factors, and to characterise its
demographic features.  
Material and methods: They were 584 cases diagnosed as MPM detected in
Cairo University Hospitals and National Cancer Institute from 1998 to 2007.
Unfortunately, full epidemiological data were only available for 165 cases due
to absence of a reliable registration system. 
Results: A steady increase in the number of cases was detected, from 24 in 1998,
peaking at 82 cases in 2005, followed by a gradual decline (though still high)
with 68 cases in 2006 and 51 cases in 2007. Male/female ratio was 1.35/1 
(p > 0.05). The occupational exposure to asbestos was 13.9%. Residential
exposure plays a major role in two regions, Helwan and Shoubra (27.3% and
20.6% respectively), while in Upper and Lower Egypt the level was 12.7% and
17.5% respectively. Kaplan-Meier survival for sex, residence and the pathological
types epithelioid, biphasic and sarcomatoid was insignificant. The median
survival for different grades and treatment modalities was significant (P < 0.001).   
Conclusions: There was a steady increase in the incidence of MPM from 1998
to 2005 followed by a decline during 2006-2007. Mesothelioma in Egypt is mainly
concentrated in areas of high environmental pollution. The decline within the
last 2 years may be attributed to recent strict industrial preventive measures.
However, a better environmental control programme would benefit Egypt.
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Introduction
Malignant pleural mesothelioma (MPM) is the most common malignant
tumour of the pleura. Mesothelioma is a cancer that is linked to exposure to
carcinogenic mineral fibres, especially asbestos and erionite. The possible role
of other mineral fibres in causing mesothelioma is being investigated [1].
The incidence of mesothelioma has gone from almost none to the
current 2500-3500 cases per year in the USA. Asbestos is considered the
main cause of mesothelioma in the US and in the western world. It is
proposed that as a consequence of the regulations to prevent exposure,
to forbid and/or limit the use of asbestos, the incidence of mesothelioma
in the US and in some European countries should have started to decline
before or around the year 2000, and sharply decline thereafter [2].
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Copyright © 2010 Termedia & BanachEpidemiological data prove that mesothelioma
incidence in Egypt is rising markedly [3]. Since
ancient times asbestos has been used in Egypt as
it was known that ancient Egyptians used it in the
mummification process [4]. There are 14 factories
dealing with asbestos in Egypt. In Cairo, the most
famous are the Siegwart factories (in Shobra El-
Khaymah and Helwan districts), which produce both
cement pipes and corrugated roofing panels
reinforced with asbestos. Asbestos-based articles
make up to 50-60% of their production. Also, the
Ora Misr factory in the city of the 10th of Ramadan
(50 km east of Cairo) uses asbestos in the
production process. In addition there is the Helwan
factory, which was built in 1927 and started to
produce asbestos articles in 1948, long before the
discovery, in 1960, that asbestos can cause
mesothelioma [5]. Asbestos is used in a variety of
everyday products. Most people cannot even identify
it, but, it is known that just several months of
concentrated exposure to this substance can cause
mesothelioma [6]. Although the lifetime risk of
developing mesothelioma among asbestos workers
is thought to be as high as 8 to 13%, there is no
direct correlation of pleural disease incidence with
the amount or duration of asbestos exposure [7].
Simian virus 40 (SV40) infection and radiation
exposure are additional causes [2]. Also, an exciting
new discovery is that genetic susceptibility to
mineral fibre carcinogenesis plays a critical role in
the incidence of this cancer in certain families [8].
The clinical course of mesothelioma is steady
deterioration to death over one to two years,
although there is some evidence that patients with
epithelial pattern have somewhat better prognosis
over the other patterns [9]. The prospects for
curative treatment are not good: management is
either by surgery, radical radiotherapy or
chemotherapy [10]. Other new therapeutic
approaches include immunotherapy [10], gene
therapy [11], hyperthermic chemoperfusion of the
pleura [10] and photodynamic therapy [12], but the
results have not yet been completely validated.
Material and methods
This retrospective study included all cases of
MPM diagnosed in the period between 1998 
and 2007 in the chest and nuclear medicine
departments of Cairo University Hospitals as well
as the National Cancer Institute, which represent
two leading medical centres for diagnosis and
treatment of cancer patients in Egypt.
The study was approved by the Human Ethics
Committee of Cairo University and all subjects gave
written informed consent before entry in the study. 
The total number of cases was 584. There were
314 cases from the National Cancer Institute, 184
cases from the chest department, and 86 cases
from the nuclear medicine department, Cairo
University. Unfortunately, due to the poor recording
system full epidemiological data were not found for
all cases. Full epidemiological data were recorded
for only 165 cases. Statistical description of each
item was done according to availability of data.
Statistical analysis 
Data were statistically described in terms of
range, mean ± standard deviation (± SD), median,
frequencies and percentages. Kaplan-Meier survival
for different parameters was done. A probability
value (P value) less than 0.05 was considered
statistically significant. All statistical calculations
were done using computer programs Microsoft
Excel 2003 (Microsoft Corporation, NY, USA) and
SPSS (Statistical Package for the Social Sciences;
SPSS Inc., Chicago, IL, USA) version 15 for Microsoft
Windows.
Results
In our study the total number of cases of MPM
in the period from January 1998 to December 2007
was 584. The incidence of MPM showed a steady
increase from 24 cases in 1998 to 82 cases in 2005
followed by a gradual decline to 51 cases in 2007
(Table I). 
Full demographic data of the 165 cases showed
that the mean age in the 165 cases was 50.78 ±13.5
years, ranging from 15 to 83 years, 94 were males
(57%) and 71 were females (43%), male/female ratio
was 1.3/1 (Table II).
Distribution of MPM by residence
Out of the 165 cases, 45 (27.3%) cases were
reported from Helwan, followed by 34 (20.6%) cases
from Shobra and in the neighbouring areas of both,
25  (15.2%) cases in Giza, and 11 (6.7%) cases in
Kaliobeya. From Upper Egypt 21 (12.7%) cases were
reported, and 29 (17.5%) cases were from other
parts of Egypt including Alexandria, Alesmaeleia,
1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 Total
No. 24 31 53 60 68 72 75 82 68 51 584
% 4.11 5.31 9.08 10.27 11.65 12.33 12.84 14.04 11.65 8.72 100
Table I. Annual incidence of mesothelioma (1998-2007)
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other than Helwan and Shobra (Table II).
Distribution of MPM by occupation
Concerning occupational risk factors only 23
(13.9%) pa  tients were working in asbestos industries
such as cement pipes, roofing and wall materials,
valves, joints, sealants, clothing, cords, strings,
clutches, brake linings and pads as well as mine
workers, while 142 (86.1%) patients were not exposed
to this hazard during working hours (Table II).
Radiological features of MPM
The main radiological features in most cases, 
102 (61.8%) cases of MPM, showed pleural thinking
with typical finger-like projections and definitely
pleural effusion which was usually unilateral and
massive; out of them a single case showed in
addition pericardial effusion. Pleural nodules were
revealed in 54 (32.8%) cases. Six (3.6%) cases were
proved by CT to have a large pleural mass with extra-
pleural extension to the chest wall. Two cases (1.2%)
presented with bilateral hilar lymphadenopathy in
addition to a large pleural mass (Table III).
Sampling techniques and histological diagnosis
of MPM
Thoracoscopy was done in 70 (42.4%)cases,
open pleural biopsy in 56 (33.9%) cases, fine needle
aspiration cytology (FNAC) in 10.3% (17 cases), 
CT-guided biopsy in 9.1% (15 cases), and Abram
biopsy in 3.6% (6 cases). A single case was
diagnosed by thoracocentesis (0.6%). 
Epithelioid mesothelioma represents the most
common histopathological subtype of MPM
diagnosed in 114 (69.1%) cases, followed by biphasic
subtype in 43 (26.1%) and sarcomatoid type in 
8 (4.8%) cases. No case was diagnosed as desmo  -
plastic. 
Concerning grades of 165 cases, the commonest
was grade II in 107 (64.8%) cases, followed by grade
III in 48 (29.1%) cases and grade I in 10 (6.1%) cases
(Table III).
Treatment modalities of MPM
Regarding the treatment modalities of the 
165 cases, chemotherapy alone was used in 
58 (53.2%) cases, surgery alone in 15 (9.1%) cases,
chemo-surgery in 43 (26.1%) cases and palliative
treatment in 49 (29.6%) cases (10 cases received
palliative radiotherapy). 
Surgery was performed in 58 cases either alone
or combined with chemotherapy, extrapleural
pneumonectomy in 49 cases, out of which in
addition pericardiectomy was performed in 3 cases,
and excision of extrathoracic swelling in another 
3 cases. Pleurectomy was the choice in 8 cases and
metastasectomy in a single case (Table IV).
Median survival of MPM patients 
(Kaplan-Meier)
Overall survival of 165 cases ranged from one
month to 52 months; the median survival duration
Item Parameter n (%)
Sex M 94  (43)
F 71 (57)
Residence Helwan 45 (27.3)
Giza (area south of Helwan) 15 (15.2)
Shoubra El-Khaymah 34 (20.6)
Kaliobeya 11  (6.7)
(area around Shoubra)
Lower Egypt 29 (17.5)
Upper Egypt 21 (12.7)
Occupational High 23  (13.9)
risk
Low 142 (86.1)
Total 165 (100)
Table II. Demographic data of the 165 cases of MPM
studied
Item Parameter n (%)
Radiological Pleural effusion & thickening* 103 (62.4)
imaging
Pleural nodules & thickening  54 (32.8)
Pleural mass with extrathoracic  6 (3.6)
extension
Hilar lymphadenopathy  2 (1.2)
& pleural mass
Biopsy Thoracoscopy  70  (42.4)
technique
Open 56 (33.9)
FNAC 17 (10.3)
CT-Guided 15 (9.1)
Abram 6 (3.6)
Thoracocentesis 1 (0.6)
Pathology Type      Epithelioid 114 (69.1)
Sarcomatoid 8 (4.8)
Biphasic 43 (26.1)
Desmoplastic –
Grade     I 10 (6.1)
II 107 (84.8)
III 48 (29.1)
Total 165 (100)
Table III. Collective radiological and pathological data
of the 165 cases of MPM studied
*A single case with pericardial effusion also
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for all the studied parameters was done. The
median survival for sex was 8.0 ±0.8 months for
females and 6.0 ±0.6 months for males. It is
statistically insignificant (Figure 1). The median
survival for histopathological type was 9.8 ±9.2
months for the epithelioid type, 7.1 ±4.8 months for
the biphasic type and 6.5 ±5.2 months for 
the sarcomatoid type. These differences were
statistically insignificant. The median survival for
different grades was 6.0 ±4.7 months for grade I,
8.0 ±0.7 months for grade II and 5.0 ±0.5 months
for grade III. The difference is statistically significant
(P < 0.001) (Figure 2). The median survival for the
treatment modalities was 8.0 ±1.0 months for
chemotherapy alone, 3.0 ±0.9 months for surgery
alone, 11.0 ±0.7 months for chemo-surgical
treatment and 4.0 ±0.3 months for supportive
therapy. The difference is statistically significant 
(P < 0.001) (Figure 3).
Discussion
Our retrospective data were collected from the
chest department and nuclear medicine department
of Cairo University Hospitals in collaboration with
the National Cancer Institute. There were 584 cases
diagnosed as MPM on a histopathological basis
during the period from January 1998 to December
2007. Full epidemiological data were only available
for 165 cases due to absence of a reliable registration
system. There was a steady increase in the number
of cases up to 2005: the incidence of MPM showed
a steady increase from 24 cases in 1998 to 82 cases
in 2005, followed by gradual decline to 51 cases in
2007. Our data support published data from the
National Cancer Institute up to year 2005 that
revealed a four-fold increase in the number of cases
of MPM for the first five years of the third millennium
in comparison to the number of cases reported over
the last ten years of the second millennium [3, 
13-15]. Unfortunately, our number of cases of MPM
detected does not represent the true actual incidence
due to the absence of a reliable registration and case
detection system in Egypt. Indeed, difficulties
associated with the sampling and diagnosis,
combined with the short survival time for MPM, may
also be res    ponsible for additional discrepancies.
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Figure 1. Kaplan-Meier survival for sex
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Management Chemotherapy 58 (35.2)
Surgical 15 (9.1)
Chemo-surgical 43 (26.1)
Palliative 49  (29.6)*
Total 165 (100)
Table IV. Descriptive data of therapeutic modalities
of the 165 cases of MPM studied
*10 patients received palliative radiotherapy
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Figure 2. Kaplan-Meier survival for grades
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Figure 3. Kaplan-Meier survival for treatment modalites
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preventive measures may explain the decline in the
number of cases in the last two years. Unfor  -
tunately, there are no data available yet to support
this work.       
A large age range (15-83 years) was observed
among the patients with MPM. The youngest was
an adolescent (15 years), living in Kaliobeya, one of
the regions associated with a high risk of
mesothelioma. He had no associated occupational
risk, was pathologically diagnosed with the
epithelioid subtype, and died after 18 months. The
median age of our patients was 50.78 ±13.5 years,
in contrast to that recorded in western countries,
which is much higher, ranging from 60 to 69 years
[13, 14]. This difference is probably due to early
residential and pollution exposure in Egypt [13]. 
The male/female ratio of our cases was 1.35/1;
there was no major gender difference (p > 0.05). In
contrast, in most western studies the male to
female ratio was about 10 : 1 [16, 17]. This difference
could be explained by the fact that most of our
patients live in polluted areas, so the chance of
exposure among both sexes is approximately equal,
with a slight preponderance in males presumably
due to spending more time outdoors in the vicinity
of asbestos plants and other occupational hazards.
Occupational exposure to asbestos played
a minor role in the epidemiology of MPM, as only
13.9% worked in industries related to asbestos,
while the majority of patients (86.1%) were not
exposed to occupational risk. Residential exposure
was found to play an important role, as most of the
patients were living in highly polluted areas; 47.9%
of our patients were living in Helwan and Shoubra,
where Siegwart factories are present. In addition,
21.9% were living in neighbouring areas of these
two regions. A study by Gafaar and Ally El-Din,
2005, has linked the high incidence of meso  the  -
lioma among people living in communities 5-7 kilo  -
metres from asbestos factories to industrial
pollution. Neighbourhood exposure to asbestos was
reported in over 80% of the cases of malignant
mesothelioma treated at the National Cancer
Institute in Cairo between 1989 and 1999 [13]. Our
data confirm that pollution and environmental
exposure to asbestos are a major issue as a cause
of MPM rather than occupational exposure in Egypt.
The limited occupational risk in our data may reflect
better preventive industrial measures inside
factories. However, a stricter adoption programme
for environmental control in Egypt is still mandatory.  
The radiological appearance of the 165 MPM
cases was comparable to the findings from the
literature [10, 18, 19]. The procedures used for
diagnosing the 165 cases of MPM were thora  co  -
scopy followed by open pleural biopsy, FNAC, 
CT-guided biopsy and Abram biopsy in 42.4%,
33.9%, 10.3%, 9.1%, 3.6% respectively. A single case
was diagnosed by thoracocentesis and pleural fluid
cytology despite the reported low sensitivity (26%)
of pleural fluid cytology to detect malignancy [10].
Medical thoracoscopy is now a common practice in
the chest department of Cairo University Hospitals
for diagnosis of pleural malignancy, since it has
a sensitivity of 91% to 98% in detecting malignant
pleural disease [10]. Currently, the most dominant
histopathological type of MPM in Egypt is the
epithelioid type followed by the biphasic and
sarcomatoid type in 69.1%, 26.1%, 4.6% respectively.
In our study no case showed desmoplastic
pathological changes. These results are compatible
with other studies reporting the highest frequency
for epithelioid type and the lowest for sarcomatoid
type [10, 13, 16]. Also, the most common treatment
modality used was chemotherapy alone or with
surgery (61.3%) followed by supportive palliative
treatment (29.6%) and lastly surgery (9.1%). 
All our patients died. The median survival was
7.0 ±0.5 months, the minimum was one month and
the maximum was 52 months. Only in one reported
case did the patient survive for about 4.5 years 
(52 months); the patient was 25 years of age, living
in Helwan, with epithelioid subtype, grade II, and
subjected to pleuropneumonectomy followed by
chemotherapy. 
Concerning the pathological type of our cases,
the overall survival among the epithelioid subtype
was about 10 months, for biphasic it was
approximately 7 months, while for sarcomatoid it
was approximately 6.5 months, and none of these
differences in survival was statistically significant.
De-Pangher et al. studied the relation between
survival and histopathological type of MPM. The
best survival was recorded in patients with the
epithelioid and biphasic types; patients with the
epithelioid type were categorized as a long-term
survival group [20]. Currently, when comparing the
overall survival to the modality of treatment, we
found that the survival time for cases subjected to
surgery was about 4 months, for cases receiving
only supportive treatment was about 9 months, for
cases receiving only chemotherapy was about 
10 months, while for cases subjected to combined
treatment was 13 months. These differences in
survival time were statistically significant, being the
best for patients receiving chemotherapy. These
results match those obtained by Cicenas et al. who,
in a study to detect the effect of treatment on MPM
survival, found that mean survival time after
combined treatment (chemotherapy and surgery)
was 12 ±2 months, compared with conservative
treatment alone, 6.0 ±2 months [21]. However, no
randomized trial has yet demonstrated a group
survival benefit for any mode of therapy or
combination of therapeutic modalities over
Yosri Akl, Safy Kaddah, Ahmed Abdelhafeez, Randa Salah, Mohamed Lotayef
930 Arch Med Sci 6, December / 2010palliative care, and most patients with pleural
mesothelioma, whether treated or untreated, will
die of complications of local disease [22]. 
Several studies have mentioned that the median
survival time was about 9.8 months depending on
the series, while 5-year survival is less than 5% 
[23-25]. In a large, population-based study, younger
age at diagnosis, female gender and epithelioid
histotype were all associated with significantly
reduced hazard ratios. Calendar period of diagnosis,
asbestos exposure and treatment were not
associated with a statistically significant impro  -
vement in survival [25]. 
In conclusion, the incidence of MPM in Egypt
steadily increased during 1998-2005, followed by
a decline in the years 2006-2007. There is a positive
link between residential location and the incidence
of MPM, which is associated with areas of heavy
pollution and environmental exposure to asbestos.
Egypt should adopt more stringent controls to
reduce pollution and rates of MPM. In addition,
accurate recording and the development of
a mandatory registration system are warranted to
determine the true size and scope of this
environmental problem in Egypt.  
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